Arteaus Therapeutics, LLC

3 articles about Arteaus Therapeutics, LLC

• Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million

  4/1/2019

  Royalty Pharma and Arteaus Therapeutics announced that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company's Emgality, an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million.

• Eli Lilly and Company Buys Back Rights To Experimental Migraine Drug From Arteaus Therapeutics, LLC

  1/13/2014

• Arteaus Therapeutics, LLC Raises $18 Million to Prevent Migraines

  10/19/2011